Immunoreactive peptide sequence from a 43 KD human cancer antigen
AssigneeJohn Wayne Cancer Institute
InventorsReiko F. Irie, Takanori Oka
Life of this patent
Estimating the term…
Loading patent…
AssigneeJohn Wayne Cancer Institute
InventorsReiko F. Irie, Takanori Oka
Estimating the term…
A tumor associated protein has been discovered to exhibit immunoreactivity to human monoclonal antibody L92. A ten amino acid peptide segment of the protein and a fourteen amino acid peptide which contains the ten amino acid peptide has also been isolated and exhibits immunoreactivity to the same antibody. Using truncated fusion proteins, the minimum recognition site for antibody binding was determined to be four amino acids. Also disclosed are polypeptide compositions against human tumors that includes the polypeptides or protein of the present disclosure, as well as antibodies reactive with these polypeptides that may be employed directly for treatment or diagnosis. A certain embodiment of the present invention is also the DNA sequence encoding the ten amino acid peptide and the DNA encoding the fourteen amino acid peptide which also exhibits immunoreactivity to human monoclonal antibody L92 and cytotoxic T cells.
A purified polypeptide segment that includes the amino acid sequence QDLTMKYQI (seq id no:9).
Dependencies are inferred from the claim text.